Lawrence Biegelsen
Stock Analyst at Wells Fargo
(1.22)
# 3,684
Out of 5,179 analysts
58
Total ratings
40.54%
Success rate
-8.98%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Lawrence Biegelsen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BDX Becton, Dickinson and Company | Maintains: Equal-Weight | $184 → $157 | $154.51 | +1.61% | 6 | Feb 10, 2026 | |
| PODD Insulet | Maintains: Overweight | $350 → $360 | $208.22 | +72.89% | 6 | Nov 7, 2025 | |
| ABT Abbott Laboratories | Maintains: Overweight | $142 → $146 | $103.99 | +40.40% | 9 | Oct 16, 2025 | |
| NPCE NeuroPace | Upgrades: Overweight | $16 → $20 | $13.34 | +49.93% | 7 | Mar 14, 2024 | |
| TNDM Tandem Diabetes Care | Maintains: Overweight | $166 → $82 | $21.00 | +290.48% | 5 | Aug 4, 2022 | |
| TFX Teleflex | Downgrades: Equal-Weight | $248 | $116.22 | +113.39% | 1 | Jul 29, 2022 | |
| ISRG Intuitive Surgical | Maintains: Overweight | $350 → $339 | $452.66 | -25.11% | 2 | Apr 22, 2022 | |
| REE REE Automotive | Initiates: Underweight | $1.5 | $0.58 | +157.03% | 1 | Mar 25, 2022 | |
| LUNG Pulmonx | Maintains: Equal-Weight | $55 → $27 | $1.17 | +2,207.69% | 3 | Feb 24, 2022 | |
| ZBH Zimmer Biomet Holdings | Maintains: Underweight | $124 → $111 | $88.57 | +25.32% | 2 | Feb 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $144 | $62.25 | +130.92% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $56 | $103.18 | -45.73% | 4 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $68 → $74 | $68.73 | +7.67% | 6 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $77 | $79.34 | -3.37% | 3 | Apr 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $85 → $90 | $10.97 | +720.42% | 1 | Mar 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $83.78 | - | 1 | Dec 12, 2019 |
Becton, Dickinson and Company
Feb 10, 2026
Maintains: Equal-Weight
Price Target: $184 → $157
Current: $154.51
Upside: +1.61%
Insulet
Nov 7, 2025
Maintains: Overweight
Price Target: $350 → $360
Current: $208.22
Upside: +72.89%
Abbott Laboratories
Oct 16, 2025
Maintains: Overweight
Price Target: $142 → $146
Current: $103.99
Upside: +40.40%
NeuroPace
Mar 14, 2024
Upgrades: Overweight
Price Target: $16 → $20
Current: $13.34
Upside: +49.93%
Tandem Diabetes Care
Aug 4, 2022
Maintains: Overweight
Price Target: $166 → $82
Current: $21.00
Upside: +290.48%
Teleflex
Jul 29, 2022
Downgrades: Equal-Weight
Price Target: $248
Current: $116.22
Upside: +113.39%
Intuitive Surgical
Apr 22, 2022
Maintains: Overweight
Price Target: $350 → $339
Current: $452.66
Upside: -25.11%
REE Automotive
Mar 25, 2022
Initiates: Underweight
Price Target: $1.5
Current: $0.58
Upside: +157.03%
Pulmonx
Feb 24, 2022
Maintains: Equal-Weight
Price Target: $55 → $27
Current: $1.17
Upside: +2,207.69%
Zimmer Biomet Holdings
Feb 8, 2022
Maintains: Underweight
Price Target: $124 → $111
Current: $88.57
Upside: +25.32%
Jan 19, 2022
Upgrades: Overweight
Price Target: $144
Current: $62.25
Upside: +130.92%
Jan 19, 2022
Upgrades: Equal-Weight
Price Target: $56
Current: $103.18
Upside: -45.73%
Oct 29, 2021
Maintains: Equal-Weight
Price Target: $68 → $74
Current: $68.73
Upside: +7.67%
Apr 28, 2020
Downgrades: Equal-Weight
Price Target: $77
Current: $79.34
Upside: -3.37%
Mar 5, 2020
Upgrades: Overweight
Price Target: $85 → $90
Current: $10.97
Upside: +720.42%
Dec 12, 2019
Upgrades: Overweight
Price Target: n/a
Current: $83.78
Upside: -